Allina Health System | Strategic Alliance Partners

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Side effect profiles driven by fruquintinib use are discussed.

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Key safety considerations for the use of fruquintinib are explored.

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

Allina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.

Allina Health Cancer Institute is excited to offer its second annual Oncology Symposium on Friday, Sept. 23, 2022. The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.